<DOC>
	<DOC>NCT02860858</DOC>
	<brief_summary>Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.</brief_summary>
	<brief_title>Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Male or Female &gt;/= 18 years Confirmed diagnosis of symptomatic macular PCV in the study eye defined by: Active macular polypoidal lesions shown by ICGA and Presence of serosanguinous maculopathy BCVA letter score between 7824 using ETDRS visual acuity chart measured at 4 meters Previous treatment with systemic antiVEGF drugs within 6 months prior to Baseline (e.g., sorafenib [Nexavar®], sunitinib [Sutent®], bevacizumab [Avastin®]) Study eye: Active ocular inflammation or infection (ocular or periocular) Uncontrolled intraocular hypertension or glaucoma (IOP&gt; 30 mmPIg) despite treatment with antiglaucoma medication Predominantlyscarred PCV lesions Ocular disorders in the study eye (e.g. cataract, retinal vascular occlusion, diabetic retinopathy) that, in the opinion of the investigator may confound interpretation of study results or compromise VA or require medical or surgical intervention during the study period Prior treatment with verteporfin PDT, externalbeam radiation, subfoveal or extrafoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy Prior treatment with any antiVEGF compound or any investigational treatment Treatment with intravitreal or subtenon corticosteroid injection or device implantation within 90 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>